Boston Scientific Corporation (BSX)
| Market Cap | 63.44B -57.0% |
| Revenue (ttm) | 20.61B +17.4% |
| Net Income | 3.57B +75.4% |
| EPS | 2.39 +74.4% |
| Shares Out | 1.49B |
| PE Ratio | 17.86 |
| Forward PE | 12.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,986,735 |
| Open | 43.31 |
| Previous Close | 43.48 |
| Day's Range | 42.25 - 43.41 |
| 52-Week Range | 42.25 - 109.50 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 75.00 (+75.73%) |
| Earnings Date | Jul 29, 2026 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for BSX stock is "Buy." The 12-month stock price target is $75.0, which is an increase of 75.73% from the latest price.
News
Boston Scientific price target lowered to $65 from $75 at Stifel
Stifel lowered the firm’s price target on Boston Scientific (BSX) to $65 from $75 and keeps a Buy rating on the shares after the firm hosted five deep left atrial…
Boston Scientific price target lowered to $67 from $100 at Jefferies
Jefferies lowered the firm’s price target on Boston Scientific (BSX) to $67 from $100 and keeps a Buy rating on the shares. The firm is lowering its Watchman growth estimates…
Boston Scientific management to meet with BTIG
Meeting to be held in New York on June 23 hosted by BTIG.
Boston Scientific price target lowered to $65 from $90 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Boston Scientific (BSX) to $65 from $90 and keeps an Overweight rating on the shares. The firm notes the…
Boston Scientific price target lowered to $61 from $68 at BofA
BofA lowered the firm’s price target on Boston Scientific (BSX) to $61 from $68 and keeps a Buy rating on the shares. Noting that the firm’s services team continues to…
Belo Sun Announces Management Transition
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Vol...
Boston Scientific price target lowered to $64 from $85 at Truist
Truist lowered the firm’s price target on Boston Scientific (BSX) to $64 from $85 and keeps a Buy rating on the shares. The firm notes the recent management commentary regarding…
Boston Scientific price target lowered to $65 from $80 at BTIG
BTIG analyst Marie Thibault lowered the firm’s price target on Boston Scientific (BSX) to $65 from $80 and keeps a Buy rating on the shares after updating the firm’s forecast…
Boston Scientific put volume heavy and directionally bearish
Bearish flow noted in Boston Scientific (BSX) with 8,246 puts trading, or 2x expected. Most active are Jun-26 47.5 puts and 6/5 weekly 47.5 puts, with total volume in those…
Boston Scientific price target lowered to $70 from $71 at Canaccord
Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $70 from $71 and keeps a Buy rating on the shares. The firm updated its model to reflect slowdowns…
Belo Sun Announces Corporate Update
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian...
Boston Scientific price target lowered to $61 from $80 at TD Cowen
TD Cowen lowered the firm’s price target on Boston Scientific (BSX) to $61 from $80 and keeps a Buy rating on the shares. The firm updated its model to account…
Boston Scientific downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Boston Scientific (BSX) to Peer Perform from Outperform without a price target The firm cut the company’s estimates to reflect the Watchman guidance reduction. It now models…
Boston Scientific price target lowered to $71 from $81 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Boston Scientific (BSX) to $71 from $81 and keeps a Buy rating on the shares after the companyprovided additional commentary on expectations…
Boston Scientific price target lowered to $70 from $87 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $70 from $87 and keeps a Buy rating on the shares. The firm cites the company’s…
Boston Scientific price target lowered to $70 from $75 at Baird
Baird lowered the firm’s price target on Boston Scientific (BSX) to $70 from $75 and keeps an Outperform rating on the shares. The firm updated its model and lowered estimates…
Boston Scientific price target lowered to $74 from $87 at Leerink
Leerink lowered the firm’s price target on Boston Scientific (BSX) to $74 from $87 and keeps an Outperform rating on the shares.
Boston Scientific price target lowered to $89 from $96 at Barclays
Barclays lowered the firm’s price target on Boston Scientific (BSX) to $89 from $96 and keeps an Overweight rating on the shares. The firm says the company yesterday set appropriate…
Boston Scientific downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Boston Scientific (BSX) to Equal Weight from Overweight with a price target of $55, down from $75. The firm sees near-term uncertainty for the…
Boston Scientific slides after flagging slowdown in Watchmen heart device usage
Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device maker flagged declining usage of its heart disease device.
Boston Scientific Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Management reaffirmed confidence in achieving margin and EPS growth despite lowering 2024 guidance due to challenges in WATCHMAN, EP, and urology. Key growth drivers include new product launches, the Penumbra acquisition, and innovation in TAVR and mapping. Robust pipeline and disciplined capital allocation support a positive long-term outlook.
Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election...
Belo Sun Provides Update on Ongoing Proceedings Before TRF-1
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th ...
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. ...